← Evidence map

ArticleFrontiers in immunology2026

M5542, a bifunctional fusion protein targeting CD80, CD86, and OX40L that modulates excessive T-cell activity: a preclinical proof-of-concept study.

Michelle Downing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

M5542, a bifunctional fusion protein targeting CD80, CD86, and OX40L that modulates excessive T-cell activity: a preclinical proof-of-concept study. | OpenQuestion